Restricted accessResearch articleFirst published online 2026-3
Towards the development of a management protocol for subjective cognitive decline: Insights from a cross-sectional and longitudinal analysis of multimodal data from a memory clinic
Subjective cognitive decline (SCD) represents the first early symptomatic stage of Alzheimer's disease (AD).
Objective
We aimed to investigate the relationships between features in SCD and to assess the importance of these features in the future development of dementia to inform a targeted management protocol.
Methods
440 SCD patients underwent neurological and neuropsychological assessments, MRI scans, APOE genotyping, and AD biomarker evaluations. Patients were followed for a median of 10 years. Relationships among features were first assessed univariately, focusing on differences across stratified subgroups. To capture multivariate associations, we applied network analysis using a Markov Random Field. Finally, baseline features were related to dementia progression using an XGboost machine learning model.
Results
Women comprising 68.9% of the cohort, were generally younger at onset, had lower APOE ε4 prevalence, and differed in neuropsychological performance compared to men. Older patients (age >60) exhibited a higher prevalence of APOE ε4 and cerebral small vessel disease. Patients with depressive symptoms demonstrated lower cognitive performance across multiple domains. Network analysis indicated complex interconnections among gender, cognitive reserve, SCD severity, and depressive symptoms. The XGboost model achieved 74% accuracy in predicting progression to dementia, identifying age at onset, mini-mental state examination scores, and APOE genotype as the most predictive factors.
Conclusions
This study highlights the role of age, gender, APOE genotype, and depressive symptoms in the presentation and progression of cognitive decline. By identifying key predictive features, we propose a personalized management protocol aimed at optimizing care for individuals with SCD.
TurveyCLSchultzSArndtS, et al.Memory complaint in a community sample aged 70 and older. J Am Geriatr Soc2000; 48: 1435–1441.
2.
ParadiseMBGlozierNSNaismithSL, et al.Subjective memory complaints, vascular risk factors and psychological distress in the middle-aged: a cross-sectional study. BMC Psychiatry2011; 11: 108.
3.
JonkerCGeerlingsMISchmandB. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry2000; 15: 983–991.
4.
AbdulrabKHeunR. Subjective memory impairment. A review of its definitions indicates the need for a comprehensive set of standardised and validated criteria. Eur Psychiatry2008; 23: 321–330.
5.
O’ConnorDWPollittPARothM, et al.Memory complaints and impairment in normal, depressed, and demented elderly persons identified in a community survey. Arch Gen Psychiatry1990; 47: 224–227.
6.
BollaKILindgrenKNBonaccorsyC, et al.Memory complaints in older adults. Fact or fiction?Arch Neurol1991; 48: 61–64.
7.
GrutMJormAFFratiglioniL, et al.Memory complaints of elderly people in a population survey: variation according to dementia stage and depression. J Am Geriatr Soc1993; 41: 1295–1300.
8.
JessenFAmariglioREvan BoxtelM, et al.A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement2014; 10: 844–852.
9.
ParfenovVAZakharovVVKabaevaAR, et al.Subjective cognitive decline as a predictor of future cognitive decline: a systematic review. Dement Neuropsychol2020; 14: 248–257.
10.
JackCRBennettDABlennowK, et al.NIA-AA Research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement2018; 14: 535–562.
11.
MitchellAJBeaumontHFergusonD, et al.Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand2014; 130: 439–451.
12.
MargolisSAKellyDADaielloLA, et al.Anticholinergic/sedative drug burden and subjective cognitive decline in older adults at risk of Alzheimer’s disease. J Gerontol A Biol Sci Med Sci2021; 76: 1037–1043.
13.
VellasBAisenPSSampaioC, et al.Prevention trials in Alzheimer’s disease: an EU-US task force report. Prog Neurobiol2011; 95: 594–600.
14.
CummingsJZhouYLeeG, et al.Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement (N Y)2023; 9: e12385.
15.
BhomeRBerryAJHuntleyJD, et al.Interventions for subjective cognitive decline: systematic review and meta-analysis. BMJ Open2018; 8: e021610.
16.
RoehrSLuckTPabstA, et al.Subjective cognitive decline is longitudinally associated with lower health-related quality of life. Int Psychogeriatr2017; 29: 1939–1950.
17.
GiffordKABellSPLiuD, et al.Frailty is related to subjective cognitive decline in older women without dementia. J Am Geriatr Soc2019; 67: 1803–1811.
18.
TaylorCA. Subjective cognitive decline among adults aged ≥45 years — United States, 2015–2016. MMWR Morb Mortal Wkly Rep2018; 67: 753–757.
19.
BubbicoGDi IorioALauriolaM, et al.Subjective cognitive decline and nighttime sleep alterations, a longitudinal analysis. Front Aging Neurosci2019; 11: 142.
20.
BouldinEDTaylorCAKnappKA, et al.Unmet needs for assistance related to subjective cognitive decline among community-dwelling middle-aged and older adults in the US: prevalence and impact on health-related quality of life. Int Psychogeriatr2021; 33: 689–702.
21.
LawtonMPBrodyEM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist1969; 9: 179–186.
22.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 263–269.
23.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 270–279.
24.
MazzeoSPadiglioniSBagnoliS, et al.Assessing the effectiveness of subjective cognitive decline plus criteria in predicting the progression to Alzheimer’s disease: an 11-year follow-up study. Eur J Neurol2020; 27: 894–899.
25.
SlotRERVerfaillieSCJOverbeekJM, et al.Subjective cognitive impairment cohort (SCIENCe): study design and first results. Alzheimers Res Ther2018; 10: 76.
26.
CampbellNLBoustaniMALaneKA, et al.Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology2010; 75: 152–159.
27.
FazekasFBarkhofFWahlundLO, et al.CT And MRI rating of white matter lesions. Cerebrovasc Dis2002; 13: 31–36.
28.
GoldbergLR. The development of markers for the big-five factor structure. Psychol Assess1992; 4: 26–42.
29.
ColomboLBrivioCBenaglioI, et al.Alzheimer patients’ ability to read words with irregular stress. Cortex2000; 36: 703–714.
30.
BrightPHaleEGoochVJ, et al.The national adult Reading test: restandardisation against the Wechsler adult intelligence scale-fourth edition. Neuropsychol Rehabil2018; 28: 1019–1027.
31.
HamiltonM. A rating scale for depression. J Neurol Neurosurg Psychiatr1960; 23: 56–62.
32.
CrookTHFeherEPLarrabeeGJ. Assessment of memory complaint in age-associated memory impairment: the MAC-Q. Int Psychogeriatr1992; 4: 165–176.
33.
YarnoldPRStilleFCMartinGJ. Cross-sectional psychometric assessment of the functional Status questionnaire: use with geriatric versus nongeriatric ambulatory medical patients. Int J Psychiatry Med1995; 25: 305–317.
34.
SorbiSNacmiasBForleoP, et al.Apoe allele frequencies in Italian sporadic and familial Alzheimer’s disease. Neurosci Lett1994; 177: 100–102.
35.
MinoshimaSDrzezgaAEBarthelH, et al.SNMMI Procedure standard/EANM practice guideline for amyloid PET imaging of the Brain 1.0. J Nucl Med2016; 57: 1316–1322.
36.
JackCRJr.AndrewsJSBeachTG, et al.Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s association workgroup. Alzheimers Dement2024; 20: 5143–5169.
37.
EpskampSFriedEI. A tutorial on regularized partial correlation networks. Psychol Methods2018; 23: 617–634.
38.
EpskampSCramerAOJWaldorpLJ, et al.Qgraph: network visualizations of relationships in psychometric data. J Stat Softw2012; 48: 1–18.
39.
PapachristouNBarnaghiPCooperBA, et al.Congruence between latent class and k-modes analyses in the identification of oncology patients with distinct symptom experiences. J Pain Symptom Manage2018; 55: 318–333.e4.
40.
EpskampSBorsboomDFriedEI. Estimating psychological networks and their accuracy: a tutorial paper. Behav Res Methods2018; 50: 195–212.
41.
ChenTGuestrinC. XGBoost: a scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, pp.785–794.
BentéjacCCsörgőAMartínez-MuñozG. A comparative analysis of XGBoost. Artif Intell Rev2021; 54: 1937–1967.
44.
CawleyGCTalbotNLC. On over-fitting in model selection and subsequent selection bias in performance evaluation. J Mach Learn Res2010; 11: 2079–2107.
45.
HossinMSulaimanMN. A review on evaluation metrics for data classification evaluations. Int J Data Min Knowl Manag Process2015; 5: 1–11.
46.
LundbergSLeeS-I. A Unified Approach to Interpreting Model Predictions. arXiv:1705.07874 2017. DOI: 10.48550/arXiv.1705.07874
47.
YangKChenGShengC, et al.Cognitive reserve, brain reserve, APOEɛ4, and cognition in individuals with subjective cognitive decline in the SILCODE study. J Alzheimers Dis2020; 76: 249–260.
48.
HuangYXueJLiC, et al.Depression and APOEɛ4 status in individuals with subjective cognitive decline: a meta-analysis. Psychiatry Investig2020; 17: 858–864.
49.
HaoLSunYLiY, et al.Demographic characteristics and neuropsychological assessments of subjective cognitive decline (SCD) (plus). Ann Clin Transl Neurol2020; 7: 1002–1012.
50.
AghjayanSLBuckleyRFVanniniP, et al.The influence of demographic factors on subjective cognitive concerns and beta-amyloid. Int Psychogeriatr2017; 29: 645–652.
51.
Lojo-SeoaneCFacalDGuàrdia-OlmosJ, et al.Effects of cognitive reserve on cognitive performance in a follow-up study in older adults with subjective cognitive complaints. The role of working memory. Front Aging Neurosci2018; 10: 189.
52.
HongYJParkKWKangD-Y, et al.Prediction of Alzheimer’s pathological changes in subjective cognitive decline using the self-report questionnaire and neuroimaging biomarkers. Dement Neurocogn Disord2019; 18: 19–29.
53.
BessiVMazzeoSPadiglioniS, et al.From subjective cognitive decline to Alzheimer’s disease: the predictive role of neuropsychological assessment, personality traits, and cognitive reserve. A 7-year follow-up study. J Alzheimers Dis2018; 63: 1523–1535.
54.
MolinuevoJLRabinLAAmariglioR, et al.Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement2017; 13: 296–311.
55.
SlotRERSikkesSAMBerkhofJ, et al.Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia. Alzheimers Dement2019; 15: 465–476.
56.
BeebeDWGroeszLWellsC, et al.The neuropsychological effects of obstructive sleep apnea: a meta-analysis of norm-referenced and case-controlled data. Sleep2003; 26: 298–307.
57.
Health Quality Ontario. Vitamin B12 and cognitive function: an evidence-based analysis. Ont Health Technol Assess Ser2013; 13: 1–45.
58.
McIntyreRSXiaoHXSyedaK, et al.The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs2015; 29: 577–589.
59.
EckerströmMGöthlinMRolstadS, et al.Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer’s disease in a memory clinic sample. Alzheimers Dement (Amst)2017; 8: 96–107.
60.
MazzeoSPadiglioniSBagnoliS, et al.The dual role of cognitive reserve in subjective cognitive decline and mild cognitive impairment: a 7-year follow-up study. J Neurol2019; 266: 487–497.
61.
TanXÅkerstedtTLagerrosYT, et al.Interactive association between insomnia symptoms and sleep duration for the risk of dementia—a prospective study in the Swedish national march cohort. Age Ageing2023; 52: afad163.
62.
RibaldiFRolandiEVaccaroR, et al.The clinical heterogeneity of subjective cognitive decline: a data-driven approach on a population-based sample. Age Ageing2022; 51: afac209.
63.
BraakHBraakE. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging1997; 18: 351–357.
64.
StewartRGodinOCrivelloF, et al.Longitudinal neuroimaging correlates of subjective memory impairment: 4-year prospective community study. Br J Psychiatry2011; 198: 199–205.
65.
GiacomucciGMazzeoSBagnoliS, et al.Matching clinical diagnosis and amyloid biomarkers in Alzheimer’s disease and frontotemporal dementia. J Personal Med2021; 11: 47.
66.
IngannatoABagnoliSMazzeoS, et al.Neurofilament light chain and intermediate HTT alleles as combined biomarkers in Italian ALS patients. Front Neurosci2021; 15: 695049.
67.
MazzeoSBagnoliSIngannatoA, et al.Plasma neurofilament light chain predicts Alzheimer’s disease in patients with subjective cognitive decline and mild cognitive impairment: a longitudinal study. J Neurol2024; 31: e16089.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
